Roots Analysis has announced the addition of “Digital Health Market:
Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of
Solution (Software Solution, Gaming Solution and Combination Solution), Type of
Therapy (Curative and Preventive), and Purpose of Solution (Medication
Replacement and Medication Augmentation” report to its list of offerings.
According to experts, digital therapeutic solutions are
primarily based on behavior modification and are designed to address a variety
of therapeutic needs across a wide range of disease indications. On the other
hand, several digital solutions have been developed to enable remote
doctor-patient consultations. Such solutions witnessed a surge in adoptions
amidst the COVID-19 pandemic.
To order this 500+ page report, which features 160+ figures
and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html
Key Market Insights
Nearly 230 digital therapeutic solutions are currently
available / under development
Close to 45% of the aforementioned solutions are standalone
software applications targeting more than 60 unique indications.
Over 85% of digital therapeutic solutions are intended to
replace medication
Such solutions are currently available / being developed to
treat neurological disorders (27%), mental health problems (24%), and certain
metabolic disorders (24%). Alternatively, some digital health products are
designed to augment the effect of conventional therapeutics and are currently
being considered for treating substance use disorders and few mental health
problems.
220+ clinical trials, focused on digital therapeutics, have
been registered since 2004
Around 80,000 patients have been
enrolled in clinical research initiatives aimed to validate the efficacy of
digital therapeutics, and generate real world evidence concerning their
efficacy and safety. Close to 50% of such trials have been / are being
conducted in the US.
Nearly USD 1.9 billion invested by both private and public
investors in this domain
~85% of the total capital raised for digital therapeutics-related
initiatives was from venture capital investors, featuring over 370
participants.
Partnership activity in this field has grown at a CAGR of
~42%, between 2015 and 2019
More than 70% of the reported deals were established after
2017, with the maximum activity being reported in 2019. Majority of the
instances captured in the report were focused on pilot product offering (29%)
and research and development agreements (21%).
North America and Europe are anticipated to capture over
70% of the market share by 2030
The market in Asia-Pacific
regions is anticipated to grow at a relatively faster pace (23.2%). In 2030,
digital solutions targeting metabolic disorders are likely to represent the
largest market share, in terms of revenues from product sales (26%), followed
by those intended for mental health problems (20%) and neurological disorders
(19%).
To request a sample copy / brochure of this report, please
visit this -
Key Questions Answered
§
§
§
§
§
§
§
§
§
The USD 8.86 billion (by 2030) financial opportunity within
the digital therapeutics market has been analyzed across the following
segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The report features inputs from eminent industry
stakeholders, according to whom, digital therapeutic solutions are likely to
witness enhanced adoption due to their broader applicability, remote guidance
and other advanced features, thereby, offering lucrative opportunities to their
developers. The report includes detailed transcripts of the discussions held
with following industry experts:
§
§
§
§
§
§
§
§
The research covers
brief profiles of key players engaged in the development of digital therapeutic
solutions; other popular industry players featured in the report include:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
For additional details, please visit
You may also be interested in the following titles:
1.
2. AI-Based Clinical Trial Solution Providers Market, 2020-2030
3.
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091